Growth factor and pro-inflammatory cytokine contents in platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), advanced platelet-rich fibrin (A-PRF), and concentrated growth factors (CGF) by unknown
RESEARCH Open Access
Growth factor and pro-inflammatory
cytokine contents in platelet-rich plasma
(PRP), plasma rich in growth factors (PRGF),
advanced platelet-rich fibrin (A-PRF), and
concentrated growth factors (CGF)
Hideo Masuki1†, Toshimitsu Okudera1†, Taisuke Watanebe1, Masashi Suzuki1, Kazuhiko Nishiyama1,
Hajime Okudera1, Koh Nakata2, Kohya Uematsu4, Chen-Yao Su3 and Tomoyuki Kawase4*
Abstract
Background: The development of platelet-rich fibrin (PRF) drastically simplified the preparation procedure of
platelet-concentrated biomaterials, such as platelet-rich plasma (PRP), and facilitated their clinical application. PRF’s
clinical effectiveness has often been demonstrated in pre-clinical and clinical studies; however, it is still controversial
whether growth factors are significantly concentrated in PRF preparations to facilitate wound healing and tissue
regeneration. To address this matter, we performed a comparative study of growth factor contents in PRP and its
derivatives, such as advanced PRF (A-PRF) and concentrated growth factors (CGF).
Methods: PRP and its derivatives were prepared from the same peripheral blood samples collected from healthy donors.
A-PRF and CGF preparations were homogenized and centrifuged to produce extracts. Platelet and white blood cell counts
in A-PRF and CGF preparations were determined by subtracting those counts in red blood cell fractions, supernatant
acellular serum fractions, and A-PRF/CGF exudate fractions from those counts of whole blood samples. Concentrations of
growth factors (TGF-β1, PDGF-BB, VEGF) and pro-inflammatory cytokines (IL-1β, IL-6) were determined using ELISA kits.
Results: Compared to PRP preparations, both A-PRF and CGF extracts contained compatible or higher levels of platelets
and platelet-derived growth factors. In a cell proliferation assay, both A-PRF and CGF extracts significantly stimulated the
proliferation of human periosteal cells without significant reduction at higher doses.
Conclusions: These data clearly demonstrate that both A-PRF and CGF preparations contain significant amounts of
growth factors capable of stimulating periosteal cell proliferation, suggesting that A-PRF and CGF preparations function
not only as a scaffolding material but also as a reservoir to deliver certain growth factors at the site of application.
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Background
Platelet-rich plasma (PRP) was originally demonstrated to
be effective in the operation of alveolar ridge augmenta-
tion and immediately spread to the fields of periodontal
and oral maxillofacial surgery [1]. This clinical application
was endorsed by evidence that several major growth fac-
tors are contained at high levels in PRP preparations.
However, for some reasons, such as low handling effi-
ciency, addition of animal-derived thrombin for clotting,
and fundamental individual differences, it has been indi-
cated that it is difficult to reproducibly control the quality
of PRP preparations at similar levels [1]. To overcome
these drawbacks, Anitua developed plasma rich in growth
factors (PRGF) by modifying the procedure of PRP prepar-
ation [2]. It simplified the preparation protocol and re-
placed animal-derived thrombin with calcium for clotting.
Platelet-rich fibrin (PRF), a self-clotted preparation of
PRP derivative, also overcame these matters. Blood sam-
ples collected in the absence of anticoagulants are im-
mediately centrifuged to form fibrin clots. This simple
preparation procedure has been widely accepted in vari-
ous medical fields and spread worldwide. Choukroun, a
developer of PRF, further modified it to an advanced
form (A-PRF), which is expected to contain a relatively
greater number of white blood cells (WBC) [3]. Because
of low-speed centrifugation, this fibrin clot is softer than
that of the original PRF. On the other hand, concen-
trated growth factors (CGF), another modified form of
PRF, are prepared by repeatedly switching the centrifu-
gation speed and are characterized as a relatively stiffer
fibrin clot [4]. Therefore, it has been anticipated that the
difference in mechanical characteristics may produce a
difference in the growth factor content.
The aim of this study was to address the question as to
whether growth factors are equally or more concentrated
in A-PRF or CGF preparations and whether these prepara-
tions function like a reservoir of major platelet-derived
growth factors as do PRP and PRGF preparations to
facilitate wound healing and tissue regeneration. Thus, we
evaluated the levels of the selected major growth factors
and pro-inflammatory cytokines in A-PRF and CGF ex-
tracts and compared the data with those of PRP and PRGF
preparations. To reduce the individual-dependent differ-
ences in the growth factor levels, we collected sufficient
volumes of peripheral blood samples from the same donors
both in the presence or absence of anticoagulants and
immediately prepared four types of platelet concentrates.
Methods
Preparation of PRP
Based on their characteristics and fractionation, the dif-
ferences among PRP and PRP derivatives are concisely
described in our previous article [1].
As previously described [5, 6], blood samples
(11.5 mL) were collected using syringes or vacuum
blood collection tubes equipped with 18G needles from
seven non-smoking, healthy, middle-aged, male volun-
teers (37 to 68 years old) three times with a 2-week
interval. Even though they are suffering from lifestyle-
related diseases and receiving medication, these donors
had no hindrance in daily life.
To quantify each blood cell component, peripheral
blood (~12.0 mL) was collected using syringes contain-
ing acid citrate dextrose solution (ACD-A) (1.5 mL;
Terumo, Tokyo, Japan). Because of its high efficiency,
PRP was prepared using FDA-approved Ycellbio PRP
preparation tubes (Ycellbio Medical Co., Ltd., Seoul,
South Korea). As previously described [7], freshly col-
lected blood samples were subjected to blood cell count
and simultaneously transferred to funnel-shaped tubes
and centrifuged at 3200 rpm (1800g) for 4 min (Table 1).
After adjusting the level of the buffy coat, the tubes were
centrifuged for an additional 4 min. The resulting PRP
fractions (buffy coat) were collected using syringes
equipped with long needles and stored at −80 °C until
determination of growth factor levels and the in vitro
bioassay using periosteal cells (n = 20). Small aliquots of
the freshly prepared PRP were subjected to blood cell
count.
The study design and consent forms for all proce-
dures performed with the study subjects were ap-
proved by the ethical committee for human subjects
at Niigata University School of Medicine in accordance
with the Helsinki Declaration of 1975 as revised in 2008.
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Preparation of PRGF
According to the manufacturer’s instructions, blood
samples (~9.6 mL) were collected from the same
volunteers using 18G needles and PRGF-Endoret®
tubes (BTI Biotechnology Institute, S.L., Miñano,
Spain), which contained 0.2 mL sodium citrate. The
tubes were centrifuged at 1850 rpm (580g) for 8 min
(Table 1) [8]. Fraction 2 (a fraction above the buffy
coat) was collected and stored at −80 °C until use.
Small aliquots of the freshly prepared PRP were sub-
jected to blood cell count.
Preparation and homogenization of A-PRF and CGF
As described previously [7, 9], blood samples (~9.5 mL)
collected without anticoagulants using vacuum plain
glass tubes (A-PRF+: Jiangxi Fenglin Medical Technology
Co. Ltd, Fengcheng, China) or conventional vacuum
plain glass tube (Plain BD Vacutainer Tube; Becton,
Dickinson and Company, Franklin Lakes, NJ, USA)
from the same donors were immediately centrifuged
by an A-PRF centrifugation system (A-PRF12: Dragon
Laboratory Instruments Ltd., Beijing, China) or a
Medifuge centrifugation system (Silfradent S. R. L.,
Santa Sofia, Italy) (for the conditions of centrifuga-
tion, see Table 1). After eliminating the red blood cell
(RBC) fractions, the resulting A-PRF and CGF clots
were placed on dry gauze to eliminate excess amounts
of serum (~10 s) and then transferred to freezing
tubes for determination of growth factor contents.
Frozen samples stored at −80 °C were then minced,
homogenized by disposable homogenizers (BioMasher
II, Nippi, Inc., Tokyo, Japan), and centrifuged at
3000 rpm for 10 min at ambient temperature. The
resulting supernatants were stored at −80 °C until
use.
For determination of blood cell counts, another set of
A-PRF/CGF clots was prepared from blood samples ob-
tained from the same donors.
Determination of blood cell counts
The numbers of blood cells were determined twice in
the process of PRP preparation using an automated
hematology analyzer (pocH-100iV diff; Sysmex, Kobe,
Japan). First, RBCs, WBCs, and platelets were counted
immediately after blood collection. Second, freshly pre-
pared PRP and PRGF samples were directly submitted
for the blood cell count. The obtained values were ad-
justed by their relative dilution factors.
As for A-PRF and CGF preparations, RBC, WBC, and
platelet counts were determined by subtracting those
counts in RBC fractions, supernatant acellular serum
fractions, and A-PRF/CGF exudate fractions from those
counts in whole blood samples, a method which we des-
ignated “indirect subtraction method.”
Determination of growth factor and cytokine levels by ELISA
The concentrations of transforming growth factor-β1
(TGF-β1), platelet-derived growth factor-BB (PDGF-
BB), and vascular endothelial growth factor (VEGF) in
frozen PRP, PRGF, A-PRF, and CGF samples were de-
termined using human TGF-β1, PDGF-BB, and VEGF
Quantikine ELISA kits (R&D Systems, Inc., Minneapolis,
MN, USA). Concentrations of interleukin-1β (IL-1β) and
interleukin-6 (IL-6) were determined using the IL-1β
human ELISA kit and IL-6 high sensitivity human ELISA
kit (Abcam, Cambridge, MA, USA).
Evaluation of cell proliferation
Because alveolar periosteum is closely contributed to
periodontal skeletal tissue regeneration, we used human
alveolar bone-derived periosteal cells for evaluation of
efficacy of the PRP derivatives. The periosteal cells were
obtained and expanded as described below. With in-
formed consent, human periosteum tissue segments were
aseptically dissected from the periodontal tissues of the
healthy buccal side of the retromolar region of the mandi-
bles of non-smoking volunteers [10]. Small periosteum
pieces were expanded to form cell-multilayered periosteal
sheets (φ30–40 mm) in humidified 5 % CO2, 95 % air at
37 °C with medium 199 (Invitrogen, Carlsbad, CA, USA)
supplemented with 10 % fetal bovine serum (FBS) (Invi-
trogen), 25 μg/mL ascorbic acid 2-phosphate, and antibi-
otics. Then, the periosteal sheets were enzymatically
digested to release single cells. The resulting cells were
further expanded in DMEM supplemented with 10 % FBS.
Single cells were seeded at a density of 1 × 104 in 6-well
plates and pre-cultured for 24 h in 1 % FBS-containing
DMEM. The medium was replaced with the same fresh
medium containing PRP, PRGF, A-PRF extract (A-PRFext)
or CGF extract (CGFext) (0.625, 1.25, 2.5, 5.0, 10 %), and
the cells were further incubated for 48 h. Because em-
bedded in fibrin gel by the treatment of PRP or PRGF,
cells were not enzymatically harvested for determining cell
counts. Instead, cells were photographed and counted in
three randomly selected views using Image-PRO Plus soft-
ware (Media Cybernetics Manufacturing, Warrendale, PA,
USA) [11] (n = 4). Although cells were not embedded in
the medium containing A-PRFext or CGFext, to compare
these efficacies with those of PRP or PRGF, cell prolifera-
tion was evaluated by the same method.
Statistical analysis
The data were reported as the mean value ± standard
deviation (SD). For multi-group comparisons, statis-
tical analyses were performed to compare the mean
values using one-way analysis of variance (ANOVA)
followed by Dunn’s or Tukey’s multiple comparison
test (SigmaPlot 12.5; Systat Software, Inc., San Jose,
CA, USA). P values <0.05 were considered significant.
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Results
Numbers of platelets in PRP and PRGF preparations are
shown in Fig. 1 (upper panel). Platelets were significantly
concentrated both in the PRP and PRGF preparations,
and the concentration rate of PRP preparations was sub-
stantially higher than that of PRGF preparations (8.79-fold
vs. 2.84-fold). Numbers of platelets in A-PRF and CGF
preparations calculated by the indirect subtraction
method are also shown in Fig. 1 (upper panel). Platelets
were significantly concentrated also in both A-PRF and
CGF preparations with the concentration rates of 17.85-
fold and 15.51-fold, respectively.
Numbers of WBCs in PRP and other PRP derivatives
are shown in Fig. 1 (lower panel). WBCs were similarly
concentrated in these platelet-concentrated preparations
(PRP: 5.51-fold, A-PRF: 11.87-fold, CGF: 8.63-fold).
However, only an exception was PRGF preparations;
WBCs were almost completely eliminated from PRGF
preparations (0.015-fold).
The concentrations of growth factors in PRP, PRGF,
A-PRF, and CGF preparations are shown in Fig. 2. The
order of growth factor levels (TGF-β1, PDGF-BB, VEGF)
were A-PRF ≥ CGF > PRP >> PRGF. PRGF preparations
contained the lowest amounts of growth factors.
The concentrations of inflammatory cytokines in PRP,
PRGF, A-PRF, and CGF preparations are shown in Fig. 3.
IL-1β in PRGF preparations was under detectable levels,
while it showed a similar level in other three prepara-
tions. For IL-6, in contrast, there were no significant dif-
ferences among these preparations.
The effects of individual PRP derivatives on the
proliferation of human periosteal cells are shown in
Fig. 4. As shown in the preceding study [12], PRP
preparations exerted a biophasic effect with the
maximal effects observed at 2.5 %, while in PRGF

































Fig. 1 Comparisons of platelet counts in whole blood (WB) samples
and PRP and PRGF, A-PRF and CGF preparations (n = 12 (A-PRF, CGF)





























































PRP          PRGF        A-PRF         CGF
Fig. 2 Concentrations of growth factors (TGF-β1, PDGF-BB, VEGF) in
PRP, PRGF, A-PRF, and CGF preparations (n = 20)
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proliferation in a dose-dependent manner (0.625–10 %).
The apparent order of potency was PRP > CGF > A-PRF
> PRGF.
Discussion
Although the growth factor contents in PRF and CGF
preparations and their bioactivities have been demon-
strated in in vitro studies by several independent groups
[8–11, 13–20], many clinicians still believe that the re-
generative effects of PRF/CGF are solely due to fibrin
clots. We speculate that this discrepancy may be caused
by two major factors. First, the initial report on PRF by
Choukroun and his co-workers showed that PDGF-BB,
TGF-β1, or IGF-I is not significantly concentrated in
PRF preparations [21]. Second, the preparation protocols
of PRF extraction are not fully disclosed in several arti-
cles and likely varied with the individual groups. In the
previous study [7], we demonstrated that intense com-
pression of PRF preparations, which is designated as
CGF preparations in this study, with dry gauze fully
removes PRF exudate and substantially reduces the con-
tent of growth factors. Therefore, we concluded that the
major source of growth factors in PRF preparations is its
exudate; however, as a minor source, growth factors are
thought to be secured by fibrin fibers.
To confirm these observations, we recently examined
the angiogenic activity of PRF/CGF preparations in
endothelial cell cultures and the chick embryo chorio-
allantoic membrane (CAM) assay [22]. As a result, it
was demonstrated that PRF/CGF preparations are some-
what more potent in angiogenesis than PRP prepara-
tions. To further assure the growth factor contents in
the self-clotted PRP derivatives, in this study, we com-
pared the growth factor contents in four types of PRP
derivatives (PRP, PRGF, A-PRF, CGF) prepared from the
same donors. The main finding of this study was that
both A-PRF and CGF preparations contained TGF-β1,
PDGF-BB, VEGF, IL-1β, and IL-6 at levels similar to or
higher than PRP preparations. The expected proliferative
effects of both A-PRF and CGF extracts were demon-
strated in the in vitro assay using human periosteal cells,
which give rise to osteoblasts involved in periodontal
skeletal regeneration. Therefore, as do PRP preparations,
these self-clotted PRP derivatives are expected to function
not only as a scaffolding material but also as a reservoir to
deliver certain growth factors and pro-inflammatory cyto-
kines at the implantation sites.
In the previous study [12], we found that PRP and
A-PRF preparations exert distinguishable actions on
periosteal cell proliferation. Because both IL-1β and
IL-6 are known to be produced by WBCs [23], and
because WBCs are not included in PRGF prepara-
tions, we thought that the bi-phasic effects of PRP
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P < 0.05
P < 0.05
Fig. 3 Concentrations of the pro-inflammatory cytokines (IL-1β, IL-6)
in PRP, PRGF, A-PRF, and CGF preparations (n = 20)
PRP derivatives (%)





















Fig. 4 Effects of PRP, PRGF, A-PRF, and CGF on the proliferation of
human periosteal cells. Cells were treated with PRP preparations,
PRGF preparations, A-PRF extracts, or CGF extracts at the indicated
doses for 48 h in 1 % FBS-containing medium. *P < 0.05 compared
with the controls without nay addition (n = 4)
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WBCs are highly concentrated in A-PRF, it is expected
that IL-1β and IL-6 are concentrated at higher levels to
exert negative effects at higher doses of A-PRF extracts in
this study. As Choukroun intended [3], we observed that
WBCs, as well as platelets, were highly concentrated in A-
PRF preparations. Similarly, WBCs were found to be con-
centrated in CGF preparations. In addition, the inflamma-
tory cytokines were not exceptionally concentrated at
higher levels in PRP preparations, and no strong positive
correlation between WBC counts and pro-inflammatory
cytokine levels was observed in PRP preparations (data
not shown). Therefore, we speculate at present that the
negative effects of PRP preparations at higher doses may
not be due to these pro-inflammatory cytokines or WBCs.
However, at the same time, we are concerned how accur-
ately the indirect subtraction method determines WBC
and platelet (PLT) counts, because this method does not
count any possible adhesion-dependent loss of blood cells
or nonuniformity of cell distributions especially in red
thrombus. Thus, further studies are needed to perform to
obtain convincing evidence to explain this discrepancy.
Conclusions
The present study clearly demonstrated that both A-PRF
and CGF preparations contained significant amounts of
growth factors, which makes us to believe that A-PRF and
CGF preparations would not only function as a scaffolding
material but also as a reservoir to deliver certain growth
factors at the site of application. Accordingly, it is expected
that these two preparations are more potently capable of
inducing angiogenesis and subsequent wound healing/
tissue regeneration than PRP preparations.
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